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Abstract
Maintaining vitamin D status without sunlight exposure is difficult without 
supplementation. This study was designed to better understand interrelationships 
between periodic cholecalciferol (vitamin D3) supplementation and immune 
function in Antarctic workers. The effect of 2 oral dosing regimens of vitamin D3 
supplementation on vitamin D status and markers of immune function were 
evaluated in people in Antarctica with no ultraviolet light exposure for 6 mo. 
Participants were given a 2,000-IU (50 µg) daily (n=15) or 10,000-IU (250 µg) 
weekly (n=14) vitamin D3 supplement for 6 mo during a winter in Antarctica. 
Biological samples were collected at baseline and at 3 and 6 mo. Vitamin D 
intake, markers of vitamin D and bone metabolism, and latent virus reactivation 
were determined. After 6 mo the mean (±SD) serum 25-hydroxyvitamin D3 
concentration increased from 56±17 to 79±16 nmol/L and 52±10 to 69±9 nmol/L in 
the 2,000-IU/d and 10,000-IU/wk groups (main effect over time P<0.001). 
Participants with a greater BMI (participant BMI range = 19-43 g/m2) had a 
smaller increase in 25-hydroxyvitamin D3 after 6 mo supplementation (P<0.05). 
Participants with high serum cortisol and higher serum 25-hydroxyvitamin D3 
were less likely to shed Epstein-Barr virus in saliva (P<0.05). The doses given 
raised vitamin D status in participants not exposed to sunlight for 6 mo, and the 
efficacy was influenced by baseline vitamin D status and BMI. The data also 
provide evidence that vitamin D, interacting with stress, can reduce risk of latent 
virus reactivation during the winter in Antarctica. 
Objectives
A key objective of this study was to determined the efficacy of a once-weekly dose 
of vitamin D3 compared to a daily dose in maintaining 25-hydroxyvitamin D3 
status.  We also tested the hypothesis that vitamin D status can influence the 
immune response that allows increased viral reactivation among Antarctic 
expeditioners. 
Methods
This study was conducted during winter in Antarctica at McMurdo Station. The 35 
subjects recruited for this study were randomly divided into 2 groups for vitamin D 
supplementation: 2000 IU/d (n = 15), 10,000 IU/week (n = 14). Some subjects (n 
= 12) did not take supplements or took ones of their own choosing. Blood 
samples were collected about every 2 mo during the winter and 5-day diet logs 
were recorded for the 5 days prior to each blood draw. Saliva samples were 
collected daily for 10 days before each blood draw for analysis of viral 
reactivation.
41 Subjects
15 Subjects:
2000 IU/d
14 Subjects:
10,000 IU/d
12 Subjects:
Own 
supplements February, June, September
• Blood draw 
• 5-d food intake log
Measurements:
• Serum 25-hydroxyvitamin D
• Serum 1,25-dihydroxyvitamin D
• Serum PTH, Serum calcium
• Salivary viral reactivation
Educational/outreach materials describing the Polar Vitamin D Study
Results
In both 2,000-IU/d and 10,000-IU/wk supplement groups, 25-hydroxyvitamin 
D3 was significantly higher than baseline (P < 0.001) after 3 and 6 mo of 
supplementation (Table 3).  The group × time interaction effect was not 
significant (P = 0.36), suggesting that changes over time were not 
significantly affected by whether participants supplemented with smaller 
daily doses versus a large weekly dose.
The mixed-effects logistic regression model evaluating the effects of 
participants’ serum cortisol and 25-hydroxyvitamin D3 concentrations on the 
probability of EBV shedding over time revealed a significant serum cortisol
by 25-hydroxyvitamin D3 concentration interaction effect (P < 0.03). For 
individuals with high serum cortisol concentration, increasing 25-
hydroxyvitamin D3 tended to reduce the likelihood of EBV shedding, relative 
to individuals with low serum cortisol concentration.
Summary
These data show that a once-daily 2,000-IU and a once-weekly 10,000-IU 
cholecalciferol (vitamin D3) supplement were equally effective in increasing 
vitamin D status in participants not exposed to sunlight for 6 mo.  The 
response to supplementation depended on both BMI and baseline vitamin D 
concentration.
Attenuating the probability of viral shedding in persons whose immune 
function is compromised has the potential to have a positive impact on many 
people on Earth in high-stress environments as well as crewmembers 
during spaceflight.  These data are the first to suggest that a higher vitamin 
D status may help protect against reactivation of latent viruses, which is 
associated with impairment of immune function. 
Reference
• Smith SM, Zwart SR, Ploutz-Snyder R, Locke J.  Letter to the Editor: Response to vitamin 
D intake: from the Antarctic to the IOM.  J Nutrition (in press).
• Zwart SR, Mehta S, Ploutz-Snyder R, Bourbeau Y, Locke J, Pierson D, Smith SM.  
Response to vitamin D supplementation during Antarctic winter is dependent on BMI, and 
can mitigate Epstein-Barr virus reactivation.  J Nutrition (in press).
• Smith SM, Gardner KK, Locke J, Zwart SR. Vitamin D supplementation during Antarctic 
winter. Am J Clin Nutr 89:1092-1098, 2009.
0 20 40 60 80 100 120
0.0001
0.01
1 Upper quartile of cortisol
Lower quartile of cortisol
Serum 25-hydroxyvitamin D (nmol/L)
Pr
ob
ab
ili
ty
 o
f E
B
V 
sh
ed
di
ng
Feb June Sept
0
20
40
60
80
100
2000 IU/d, BMI <28 (n=10)
2000 IU/d, BMI >28 (n=5)
10000 IU/w k, BMI <28 (n=8)
10000 IU/w k, BMI >28 (n=6)
25
-h
yd
ro
xy
vi
ta
m
in
 D
(n
m
ol
/L
)
0 1000 2000 3000
0
20
40
60
80
100
120
Vitamin D intake, IU/d
Ac
hi
ev
ed
 s
er
um
25
-h
yd
ro
xy
vi
ta
m
in
 D
, n
m
ol
/L
Non-obese
Obese
Figure 3. Response of serum 25-hydroxyvitamin D to total vitamin 
D intake after about 6 months of intervention.  Each data point 
represents an individual from one of our two studies of vitamin D 
in the Antarctic.  Predicted CIs are shown as dotted lines for non-
obese (BMI < 30) subjects and as solid lines for obese subjects 
(BMI ≥ 30).  For the obese subjects, the relationship for achieved 
vitamin D is 9.1 x ln (total vitamin D intake) with predicted 
confidence intervals (shown as dashed and solid lines) for upper 
and lower intervals of y = 9.4 ln (total vitamin D intake) – 12.7 ±
(0.52 ln (total vitamin D intake).  For the non-obese subjects, the 
relationship for achieved vitamin D is 9.1 ln (total vitamin D intake) 
– 12.71 with predicted upper and lower confidence intervals of y = 
9.4 ln (total vitamin D intake) ± 0.52 ln (total vitamin D intake).  
min D to total vitamin D intake after about 6 months of intervention.  Each data point represents an individual from one of our two studies of vitamin D in the Antarctic (3, 4).  Predicted CIs are shown as dotted lines for non-obese (BMI < 30) subjects and as solid lines for obese subjects (BMI ≥ 30). For the obese subjects, the relationship for achieved vitamin D is 9.1 x ln (total vitamin D intake) with predicted confidence intervals (shown as dashed and solid lines) for upper and lower intervals of y = 9.4 ln (total vitamin D intake) – 12.7 ± (0.52 ln (total vitamin D intake).  For the non-obese subjects, the relationship for achieved vitamin D is 9.1 ln (total vitamin D intake) – 12.71 with predicted upper and lower confidence intervals of y = 9.4 ln (total vitamin D intake) 
Figure 2. The interaction of serum cortisol with the relationship 
between study participants’ 25-hydroxyvitamin D3 status and the 
probability of Epstein-Barr virus (EBV) shedding.  Data from all 
41 participants were included in this graph.  As described in the 
text, the data were statistically analyzed over the continuum of 
cortisol data, but were split into subgroups to visually present the 
relationship here.   
Figure 1. Serum 25-hydroxyvitamin D3, at baseline and 3 and 
6 mo after supplementation began, for participants with BMI 
<28 kg/m2 or >28 kg/m2 in groups taking vitamin D3 in a once-
daily dose of 2,000 IU or a once-weekly dose of 10,000 IU.  
Values are means ± SD.  As described in the text, the data 
were analyzed over the continuum of BMI statistically, but were 
split into subgroups to visually present the relationship here.  
The change in serum 25-hydroxyvitamin D3 after 6 mo of 
supplementation was greater for participants with lower BMI 
than for those with higher BMI (P < 0.03). 
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